Erica Monaco departed as Chief Executive Officer at Biofrontera Inc..
“Erica Monaco, Chief Executive Officer of the Company notified the Company’s Board of Directors that she intends to resign from the Company to pursue other opportunities.”
Biofrontera Inc. — fact timeline
Source-grounded facts extracted from Biofrontera Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Biofrontera Inc. amended Amendment No. 1 to the Stockholder Rights Agreement with Computershare Trust Company, N.A., as Rights Agent (effective 2023-04-26).
“On April 26, 2023, Biofrontera Inc., a Delaware corporation (the "Company") and Computershare Trust Company, N.A., as Rights Agent, executed Amendment No. 1 to the Stockholder Rights Agreement (the "Amendment"), effective as of April 26, 2023.”
Biofrontera Inc. entered into Settlement Agreement with Biofrontera AG valued at settlement of disputes related to stockholder meetings and director nominations (effective 2023-04-11).
“On April 11, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), and each member of its Board of Directors, in their individual capacities, entered into a settlement agreement (the “Settlement Agreement”) with Biofrontera AG, a significant stockholder of the Company.”
Biofrontera Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $10.1 million, net income $2.8 million. Guidance raised.
“at least 25% over last year positioning us well to be cashflow positive within approximately two years.” Fourth Quarter Financial Results Fourth quarter 2022 total revenues of $10.1 million, compared with $9.2 million in the fourth quarter of 2021. The increase was driven by continued growth in the sales of Ameluz, partially offset by shipping delays and some sales”
Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 24, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un”
Biofrontera Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $10.2 million to $10.4 million.
“Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022. Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021. These projections result in 2022 revenue of approximately $28.7 million to $28.9 million, a record high and up approximately 20% compared with 2021.”
Biofrontera Inc. shareholders approved Ratification of Appointment of Independent Public Accounting Firm at the 2022-12-12 meeting.
“3. Ratification of Appointment of Independent Public Accounting Firm For Against Abstain Broker Non-Votes 10,267,203 2,059,792 127,393 N/A As a result, the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified.”
Biofrontera Inc. shareholders approved Approval of Amendment to Increase the Number of Shares of Common Stock Authorized for Issuance under the Plan at the 2022-12-12 meeting.
“2.Approval of Amendment to Increase the Number of Shares of Common Stock Authorized for Issuance under the Plan For Against Abstain Broker Non-Votes 4,768,084 4,739,209 13,907 2,933,188 As a result, the Amendment was duly approved by the Company’s stockholders and effective as of December 12, 2022, the total number of shares authorized for issuance under the Plan was increased to 5,339,800 shares of stock.”
Biofrontera Inc. shareholders approved Election of Loretta Wedge as Class I Director at the 2022-12-12 meeting.
“1.Election of Loretta Wedge as Class I Director For Withheld Broker Non-Votes 7,486,331 2,034,869 2,933,188 As a result, Ms. Wedge was elected for a term expiring at the 2025 annual meeting of stockholders or until her earlier death, resignation or removal.”
Biofrontera Inc. reported Fiscal year ending December 31, 2022 results: revenue total revenues for 2022 to increase between 24% and 31% compared with 2021. Guidance initiated.
“With year-to-date revenues up 24%, we expect total revenues for 2022 to increase between 24% and 31% compared with 2021, inclusive of seasonal strength in the first and fourth quarters.”
Biofrontera Inc. reported Third quarter ended September 30, 2022 results: revenue Total revenues $4.3 million, net income Net loss $2.6 million, EPS $0.11 per share.
“Total revenues for the third quarter of 2022 of $4.3 million were consistent with the third quarter of 2021. Total operating expenses were $8.0 million for the third quarter of 2022, compared with $20.4 million for the third quarter of 2021. Cost of revenues decreased by 3% primarily due to lower Ameluz sales. Selling, general and administrative expenses decreased by $9.3 million, or 54%, compared with the prior year primarily due to a one-time legal settlement expense in 2021, partially offset by higher business insurance and headcount costs as a result of resumed hiring in 2022. Net loss for the third quarter of 2022 was $2.6 million, or $0.11 per share, compared with a net loss of $16.0 million, or $2.00 per share, for the third quarter of 2021.”
Fred Leffler was appointed as Chief Financial Officer at Biofrontera Inc..
“On October 24, 2022, Biofrontera Inc. (the “Company”) announced that, effective as of that date, Fred Leffler has been appointed as Chief Financial Officer of the Company.”
Kevin D. Weber was appointed as Class II Director at Biofrontera Inc..
“On March 2, 2022, the board of directors (“Board”) of Biofrontera Inc. (the “Company”) voted to increase the size of the Board from four directors to five directors and appointed Kevin D. Weber to fill the vacancy resulting from such increase.”
Loretta M. Wedge was appointed as Director at Biofrontera Inc..
“John J. Borer, Beth J. Hoffman, Ph.D, and Loretta M. Wedge, CPA, CCGMA (collectively, the “Directors”) were appointed to the board of directors of the Company”
Beth J. Hoffman was appointed as Director at Biofrontera Inc..
“John J. Borer, Beth J. Hoffman, Ph.D, and Loretta M. Wedge, CPA, CCGMA (collectively, the “Directors”) were appointed to the board of directors of the Company”
John J. Borer was appointed as Director at Biofrontera Inc..
“John J. Borer, Beth J. Hoffman, Ph.D, and Loretta M. Wedge, CPA, CCGMA (collectively, the “Directors”) were appointed to the board of directors of the Company”
Erica Monaco resigned as Director at Biofrontera Inc..
“Erica Monaco resigned her position on the board of directors of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.